Age (year): n, median [25th -75th percentile] | 214, 79 [75 - 82] |
Women, n (%) | 132 (61.7) |
Social status | |
alone, n (%) | 93 (44.9) |
with partner, n (%) | 108 (52.2) |
other*, n (%) | 6 (2.9) |
CIRS (score): n, median [25th -75th percentile] | 214, 6.0 [4.0- 8.0] |
Number of medications beside ChEI | |
≤4, n (%) | 100 (46.9) |
>4 (polypharmacy), n (%) | 113 (53.1) |
Use of informal care, n (%) | 182 (85.4) |
Use of professional care, n (%) | 99 (46.9) |
MMSE (score): n, median [25th -75th percentile] | 212, 23 [20 - 25] |
MMSE score ≤24, n (%) | 138 (65.1) |
MMSE >26, n (%) | 33 (15.6) |
Mild AD (MMSE 21 - 26), n (%) | 126 (59.4) |
Moderate AD (MMSE 10 - 20), n (%) | 53 (25.0) |
Moderate severe AD (MMSE 10 - 14), n (%) | 3 (1.4) |
Severe AD (MMSE <10), n (%) | 0 (0) |
Clock-drawing test (score): n, median [25th -75th percentile] | 193, 3.0 [2.0 - 4.5] |
Clock-drawing test score ≥3, n (%) | 140 (72.5) |
Presence of BPS, n (%) | 51 (24.4) |
ChEI which was started | |
galantamine, n (%) | 209 (97.7) |
rivastigmine, n (%) | 5 (2.3) |
Weight (kg): n, mean ± SD | 214, 73.8 ± 12.0 |
BMI (weight/(height)2): n, median [25th -75th percentile] | 203, 25.8 [23.5 - 28.6] |
Use of ONS, n (%) | 1 (0.5) |
Appetite | |
good, n (%) | 170 (92.9) |
poor, n (%) | 13 (7.1) |
Self-reported weight loss, n (%) | 28 (14.4) |
Left MTA score | |
0 (no atrophy), n (%) | 1 (0.5) |
1 (mild atrophy), n (%) | 15 (7.0) |
2 (moderate atrophy), n (%) | 111 (51.9) |
3 (severe atrophy), n (%) | 65 (30.4) |
4 (very severe atrophy), n (%) | 22 (10.3) |
Right MTA score | |
0 (no atrophy), n (%) | 2 (0.9) |
1 (mild atrophy), n (%) | 15 (7.0) |
2 (moderate atrophy), n (%) | 108 (50.5) |
3 (severe atrophy), n (%) | 74 (34.6) |
4 (very severe atrophy), n (%) | 15 (7.0) |